In addition, the Group's subsidiary Viva Biotech Shanghai was successfully restructured into a joint stock limited company on September 27, 2024, as the Group currently holds approximately 72.9% of ...

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

Recent advancements in cancer therapy focus on targeting critical mutations and regulatory pathways, particularly KRAS mutations and cyclin-dependent kinases (CDKs), which drive cancer progression.

Targeted protein degradation is a therapeutic strategy that utilizes the cell’s natural machinery to eliminate disease-causing proteins. The field traces its origins to the development of ...

Nucleic acid therapeutics are based on nucleic acids or closely related chemical compounds. They include antisense oligonucleotides, aptamers and small interfering RNAs, and are typically ...

Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues ...

Humanwell Healthcare (Group) Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

This month's cover highlights the article Boosting human immunology: Harnessing the potential of immune organoids by Dirk Baumjohann and Maximilian Moll. The review article explores recent advances in ...

Ubiquitins are essential proteins that regulate cellular functions by marking other proteins for degradation, thereby maintaining homeostasis. Targeted Protein Degradation (TPD) leverages this ...

In this illustration we see Oerth Bio's PROTAC molecule linking between a target protein (r) and an E3 ubiquitin ligase (l), signalling for a ubiquitin molecule to be attached to the protein, marking ...